Tech Company Financing Transactions

Sidewinder Therapeutics Funding Round

Frazier Life Sciences, Novartis Venture Fund and Alexandria Venture Investments participated in a $137 million Series B venture round for Sidewinder Therapeutics. The round was recorded on 4/8/2026.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

1625 N. Market Blvd. S-202
Sacramento, CA 95834
USA

Phone

(800) 952-5210

Website

www.sidewinderbio.com

Email Address

[email protected]

Overview

Sidewinder Therapeutics is pioneering the next generation of bispecific antibody-drug conjugates. We aim to deliver next-generation bispecific antibody-drug conjugates (ADCs) that expand the therapeutic window for patients with difficult to treat cancers. Built by a dynamic team of serial entrepreneurs, expert scientists and drug developers, we are advancing bispecific ADCs engineered to target receptor co-complexes that are highly expressed on certain solid tumors with enhanced tumor cell specificity and internalization.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Eric Murphy

        

Co-Founder

Ryan Corcoran

        

President

Rob McRae

        

VP - General Counsel

Michael Mueller

        

Browse more venture capital transactions:

Prev: 4/7/2026: Gulf Coast Midstream Partners venture capital transaction
Next: 4/8/2026: Incyclix Bio venture capital transaction

Share this article

Where The Data Comes From

Our team works diligently to report on every notable VC transaction. VC investment data records reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary